Press Releases
See the latest Press Releases from Perspective Therapeutics.
Perspective Therapeutics Announces Changes to the Board of Directors
* Heidi Henson was appointed to the Board of Directors and named Audit Committee Chair taking over from Rob Williamson, III, who will continue to serve as a member of the Committee
* Michael McCormick announced his resignation and amicable departure from the Board of Directors
Perspective Therapeutics Expands Management Team And Names Andrew Bright as Executive Vice-President of Brachytherapy
The grant from the Medical Research Council (MRC) of the United Kingdom (part of UK Innovation and Research; UKRI) is supporting preclinical in vitro and in vivo studies of [212Pb]VMT-𝛼-NET for neuroendocrine tumors (NETs) Funds from the award are directed to Perspective Therapeutics’ collaborator Dr. Samantha Terry PhD, an...
Perspective Therapeutics and PharmaLogic announce collaboration for the development and production of theranostics for cancer care
The grant from the Medical Research Council (MRC) of the United Kingdom (part of UK Innovation and Research; UKRI) is supporting preclinical in vitro and in vivo studies of [212Pb]VMT-𝛼-NET for neuroendocrine tumors (NETs) Funds from the award are directed to Perspective Therapeutics’ collaborator Dr. Samantha Terry PhD, an...
Perspective Therapeutics Announces the Awarding of a $1 million Collaborative Grant to King’s College London to Support Radiobiology Research of Alpha Particle Therapy for Cancer
The grant from the Medical Research Council (MRC) of the United Kingdom (part of UK Innovation and Research; UKRI) is supporting preclinical in vitro and in vivo studies of [212Pb]VMT-𝛼-NET for neuroendocrine tumors (NETs) Funds from the award are directed to Perspective Therapeutics’ collaborator Dr. Samantha Terry PhD, an...
Initial Results From First Patient Dosed With Perspective Therapeutics’ Lead Drug VMT-α-NET Presented at The Treatment of Neuroendocrine Disorders at the 2023 PET/RTRC Annual Workshop Scientific Session
The result from first patient dosed with VMT-α-NET in India on a compassionate use basis showed favorable responses. The initial response was measured by a somatostatin imaging agent 68Ga-DOTANOC and demonstrated surprisingly favorable results after a single low dose of 212Pb-VMT-a-NET. RICHLAND, WASHINGTON & CORALVILLE, IOWA – February 22,...
Isoray Announces Results of Fiscal 2023 Annual Meeting of Stockholders
In early December, VMT-α-NET, the Company’s lead drug for the treatment of neuroendocrine tumors was administered to patients in India on a compassionate use basis, independent of a planned US trial…
Viewpoint Molecular Targeting Announces First Neuroendocrine Tumor Patients Dosed with Therapeutic Intent
In early December, VMT-α-NET, the Company’s lead drug for the treatment of neuroendocrine tumors was administered to patients in India on a compassionate use basis, independent of a planned US trial…
Isoray Announces Adjournment of Annual Meeting of Stockholders to January 27, 2023
Always strive for better work. Never stop learning. Have fun a clear plan for a new project or just an idea on a napkin? Sky, land, and sea disappear together out of the world…
